Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667002 | SCV000791387 | uncertain significance | Alstrom syndrome | 2017-05-10 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000667002 | SCV001202746 | uncertain significance | Alstrom syndrome | 2022-08-19 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 2855 of the ALMS1 protein (p.Leu2855Val). This variant is present in population databases (rs765176591, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with ALMS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 551846). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002442395 | SCV002680379 | uncertain significance | Cardiovascular phenotype | 2022-06-30 | criteria provided, single submitter | clinical testing | The p.L2855V variant (also known as c.8563C>G), located in coding exon 10 of the ALMS1 gene, results from a C to G substitution at nucleotide position 8563. The leucine at codon 2855 is replaced by valine, an amino acid with highly similar properties. This variant was reported in an Alstrom syndrome cohort; however details were limited (Marshall JD et al. Hum Mutat, 2015 Jul;36:660-8). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000667002 | SCV001453029 | uncertain significance | Alstrom syndrome | 2020-09-16 | no assertion criteria provided | clinical testing |